In vivo survival of K:18 red cells in a recipient with anti‐K 18

C. Barrasso; H. Drew; P. M. Ness

doi:10.1046/j.1537-2995.1983.23383224910.x

In vivo survival of K:18 red cells in a recipient with anti‐K 18

C. Barrasso, H. Drew, P. M. Ness

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Red cell survival, IgG subclass, and mononuclear phagocyte assay studies were performed on a patient with an antl‐K + K18 described previously. The ⁵¹Cr survival study with Kell negative K:18 red cells showed 76.6 percent survival at 75 minutes with 30.7 percent survival at 24 hours. The anti‐K18 was characterized as lgG4 + lgG1. The mononuclear phagocyte assay was 16 percent when the serum was tested with K:18 cells. Among 54,450 ABO compatible donor units tested with this serum, no K:18‐ unit was found. These studies were undertaken to evaluate the clinical significance of the antibody when red cell support for a chemotherapy course was considered. Our data suggest that transfusion with K:18+ blood would be ineffective and could be used only to provide red cell support in an emergency should compatible units be unavailable. 1983 AABB

Original language	English (US)
Pages (from-to)	258-259
Number of pages	2
Journal	Transfusion
Volume	23
Issue number	3
DOIs	https://doi.org/10.1046/j.1537-2995.1983.23383224910.x
State	Published - 1983

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Hematology

Access to Document

10.1046/j.1537-2995.1983.23383224910.x

Cite this

@article{489dba8a810242e19d7fe1193c8feaa6,

title = "In vivo survival of K:18 red cells in a recipient with anti‐K 18",

abstract = "Red cell survival, IgG subclass, and mononuclear phagocyte assay studies were performed on a patient with an antl‐K + K18 described previously. The 51Cr survival study with Kell negative K:18 red cells showed 76.6 percent survival at 75 minutes with 30.7 percent survival at 24 hours. The anti‐K18 was characterized as lgG4 + lgG1. The mononuclear phagocyte assay was 16 percent when the serum was tested with K:18 cells. Among 54,450 ABO compatible donor units tested with this serum, no K:18‐ unit was found. These studies were undertaken to evaluate the clinical significance of the antibody when red cell support for a chemotherapy course was considered. Our data suggest that transfusion with K:18+ blood would be ineffective and could be used only to provide red cell support in an emergency should compatible units be unavailable. 1983 AABB",

author = "C. Barrasso and H. Drew and Ness, {P. M.}",

year = "1983",

doi = "10.1046/j.1537-2995.1983.23383224910.x",

language = "English (US)",

volume = "23",

pages = "258--259",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - In vivo survival of K:18 red cells in a recipient with anti‐K 18

AU - Barrasso, C.

AU - Drew, H.

AU - Ness, P. M.

PY - 1983

Y1 - 1983

N2 - Red cell survival, IgG subclass, and mononuclear phagocyte assay studies were performed on a patient with an antl‐K + K18 described previously. The 51Cr survival study with Kell negative K:18 red cells showed 76.6 percent survival at 75 minutes with 30.7 percent survival at 24 hours. The anti‐K18 was characterized as lgG4 + lgG1. The mononuclear phagocyte assay was 16 percent when the serum was tested with K:18 cells. Among 54,450 ABO compatible donor units tested with this serum, no K:18‐ unit was found. These studies were undertaken to evaluate the clinical significance of the antibody when red cell support for a chemotherapy course was considered. Our data suggest that transfusion with K:18+ blood would be ineffective and could be used only to provide red cell support in an emergency should compatible units be unavailable. 1983 AABB

AB - Red cell survival, IgG subclass, and mononuclear phagocyte assay studies were performed on a patient with an antl‐K + K18 described previously. The 51Cr survival study with Kell negative K:18 red cells showed 76.6 percent survival at 75 minutes with 30.7 percent survival at 24 hours. The anti‐K18 was characterized as lgG4 + lgG1. The mononuclear phagocyte assay was 16 percent when the serum was tested with K:18 cells. Among 54,450 ABO compatible donor units tested with this serum, no K:18‐ unit was found. These studies were undertaken to evaluate the clinical significance of the antibody when red cell support for a chemotherapy course was considered. Our data suggest that transfusion with K:18+ blood would be ineffective and could be used only to provide red cell support in an emergency should compatible units be unavailable. 1983 AABB

UR - http://www.scopus.com/inward/record.url?scp=0020549082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020549082&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.1983.23383224910.x

DO - 10.1046/j.1537-2995.1983.23383224910.x

M3 - Article

C2 - 6679384

AN - SCOPUS:0020549082

SN - 0041-1132

VL - 23

SP - 258

EP - 259

JO - Transfusion

JF - Transfusion

IS - 3

ER -

In vivo survival of K:18 red cells in a recipient with anti‐K 18

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this